Open an account

Exicure

XCUR · NASDAQ

$0.9987−$0.0313 (−3.04%)TodayMarket closed ·
Prev close $1.03

About XCUR

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 8 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.

Employees
8
Headquarters
Chicago, Illinois
Listed
May 9, 2018
Sector
Health Care
Industry
Biotechnology
Website
exicuretx.com

XCUR key statistics

Market cap
10.01M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
35.28K
Volume
47.86K
Open price
$1.11
High today
$1.11
Low today
$0.9901
52 Week high
$9.48
52 Week low
$0.936

Exicure (XCUR) at a glance

As of Oct 20, 2026, Exicure (XCUR) shares are priced at $0.9987, giving the company a market cap of 10.01M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.9901 and $1.11. The current price is 0.9% above the day's low and 10.0% below its high.

Volume so far is 47.86K shares, above the average of 35.28K shares a day.

Over the past year Exicure has ranged from $0.936 to $9.48, and now sits 1% of the way up that range.

Exicure met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY22 it reported -$8.30 per share against an estimate of -$6.12.

XCUR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 2.0% on average.

  1. Q3 FY20: reported -$15.00 per share against an estimate of -$14.15
  2. Q4 FY20: reported -$21.00 per share against an estimate of -$15.91
  3. Q1 FY21: reported -$21.00 per share against an estimate of -$19.13
  4. Q2 FY21: reported -$24.00 per share against an estimate of -$21.42
  5. Q3 FY21: reported -$40.50 per share against an estimate of -$14.53
  6. Q4 FY21: reported -$22.50 per share against an estimate of -$21.42
  7. Q1 FY22: reported -$10.50 per share against an estimate of -$10.71
  8. Q2 FY22: reported -$8.30 per share against an estimate of -$6.12

XCUR news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Avi Kapoor

    Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

  • Avi Kapoor

    Crude Oil Down 1%; AutoZone Shares Dip After Q1 Results

  • Vandana Singh

    Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

  • Avi Kapoor

    Dow Surges Over 100 Points; Campbell's Posts Upbeat Earnings

  • Market-Moving News for December 9th

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as Exicure

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.